Is Dogwood Therapeutics, Inc. (DWTX) a Buy, Sell, or Hold?
NASDAQ : DWTX
Dogwood Therapeutics, Inc.
$1.84 USD
$0.04 (2.22%)
- Volume
- 0
- Average Volume
- 91.62K
- Market Capitalization
- $61.88M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.50
- Year Low
- $1.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.86
Company Overview
NASDAQ
Gregory Duncan
Biotechnology
Healthcare
DWTX
8
US
USD
Liquidity Metrics
0.00
5.86
5.86
5.17
0.00
Sales & Valuation
-$
0.00
0.77
-3.99
-0.46
Profitability
-$4.32
-$34.26M
0.00%
0.00%
-35.91%
-29.74%
P/E Metrics
-0.17
-0.01
-0.01
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-2.34
2/9
$12.44M
$95.21M
$14.58M
-$28.29M
Key Metrics (TTM)
-$9.59M
0.00
0.34
5.86
-35.91%
-30.87%
-46.13%
-443.85%
0 days
Company Executives
| Name | Title |
|---|---|
| R. Michael Gendreau | Chief Medical Officer |
| William L. Pridgen | Founder & Member of Scientific Advisory Board |
| Gregory Duncan | Chairman & Chief Executive Officer |
| Ralph D. Grosswald | Senior Vice President of Operations |
| Angela Walsh | Chief Financial Officer, Secretary & Treasurer |
| Carol Duffy | Chief Scientific Advisor |
Poll Results
No votes yet today — be the first to share your view!
About Dogwood Therapeutics, Inc. (NASDAQ:DWTX) Stock
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company main ... tains its main office in Alpharetta, Georgia.
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next?
2026-08-04 02:03:42
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) shares traded up 4.3% during trading on Monday. The stock traded as high as $1.74 and last traded at $1.71. Approximately 83,119 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 68,704 shares. The stock had previously closed at
2026-07-20 08:30:00
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.
2026-06-30 08:45:00
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-16 12:02:09
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
2026-05-18 08:45:00
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
2026-05-14 08:30:00
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
Frequently Asked Questions
-
What is the current Dogwood Therapeutics, Inc. (DWTX) stock price?
-
Dogwood Therapeutics, Inc.(NASDAQ:DWTX) stock price is $1.84 in the last trading session. During the trading session, DWTX stock reached the peak price of $9.5 while $1.28 was the lowest point it dropped to. The percentage change in DWTX stock occurred in the recent session was 2.22% while the dollar amount for the price change in DWTX stock was $0.04.
-
DWTX's industry and sector of operation?
-
The NASDAQ listed DWTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DWTX?
-
R. Michael Gendreau | Chief Medical Officer
William L. Pridgen | Founder & Member of Scientific Advisory Board
Gregory Duncan | Chairman & Chief Executive Officer
Ralph D. Grosswald | Senior Vice President of Operations
Angela Walsh | Chief Financial Officer, Secretary & Treasurer -
How many employees does DWTX have?
-
Number of DWTX employees currently stands at 8. DWTX operates from 44 Milton Avenue, Alpharetta, GA 30009, US.
-
Link for DWTX official website?
-
Official Website of DWTX is: https://www.dwtx.com
-
How do I contact DWTX?
-
DWTX could be contacted at phone #866 620 8655 and can also be accessed through its website. DWTX operates from 44 Milton Avenue, Alpharetta, GA 30009, US.
-
How many shares of DWTX are traded daily?
-
The average number of DWTX shares traded daily for last 3 months was 91.62K.
-
What is the market cap of DWTX currently?
-
The market value of DWTX currently stands at $61.88M with its latest stock price at $1.84